20 years of glycobiology. Validated by Japan's PMDA in 2026. Ready for global partnership.
The antibody binds the glycan, not one specific protein — so a single ADC can address a tumor-associated signature carried by many different receptors and membrane proteins at once.
Because the target is the sugar rather than any one protein, a tumor cannot escape treatment simply by downregulating a single receptor.
Glycan-directed targeting can reach tumor-associated markers that conventional protein-directed ADCs are unable to address.
GlycoNex's core capability is discovering antibodies against tumor-associated carbohydrate antigens. These anti-glycan antibodies anchor a pipeline of ADCs, pro-antibody ADCs, and bispecific ADCs — led by GNX1021, now in Phase 1.
Explore the pipeline →Contract development and manufacturing from a 50 L + 200 L GMP antibody facility: cell-line development, upstream and downstream process development, scale-up, and technology transfer for external partners.
CDMO services →Two biosimilar programs: SPD8 (denosumab biosimilar, Phase 3 complete), co-developed with Mitsubishi Gas Chemical; and SSR, a biosimilar for an autoimmune disease, developed in-house.
View biosimilars →One of the most extensive collections of anti-glycan monoclonal antibodies — over 50 to date — accumulated through two decades of dedicated research.
Learn more →Antibody-drug conjugates that pair GlycoNex's anti-glycan antibodies with clinically validated linker technology, directed at tumor-associated carbohydrate antigens that distinguish malignant from healthy cells.
Learn more →In-house GMP-compliant antibody production for Phase 1 clinical supply and external CDMO partners.
Learn more →GlycoNex's denosumab biosimilar met its Phase 3 primary endpoint in Japan, confirming clinical comparability to the reference product.
Read →Japan's Pharmaceuticals and Medical Devices Agency has authorized first-in-human dosing for GlycoNex's lead glycan-targeted ADC in patients with refractory GI cancers.
Read →Strategic preclinical collaboration on a next-generation pro-antibody ADC, with Nippon Kayaku contributing payload chemistry expertise.
Read →Building on SPD8 manufacturing experience, GlycoNex extends its biosimilar portfolio toward a high-volume immunology target.
Read →GlycoNex is actively seeking global licensing and co-development partners across our Phase 1+ pipeline.
Get in Touch →